Study to Evaluate Effectiveness of Brensocatib for Bronchiectasis
The BEST-BE observational study will track 1,000 bronchiectasis patients to measure the impact of brensocatib on pulmonary exacerbations and patient quality of life.
The BEST-BE observational study will track 1,000 bronchiectasis patients to measure the impact of brensocatib on pulmonary exacerbations and patient quality of life.
The BEST-BE observational study will track 1,000 bronchiectasis patients to measure the impact of brensocatib on pulmonary exacerbations and patient quality of life.
Read MoreA new class of drugs offers a disease-based approach to managing non-cystic fibrosis bronchiectasis by targeting airway inflammation.
Read MoreThe phase 3 ASPEN trial revealed brensocatib 10 mg and 25 mg significantly reduced bronchiectasis exacerbations, prolonged time to first exacerbation, and improved quality-of-life scores.
Read More